A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
- Status
- COMPLETED
- Phase
- N/A
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)
- Status
- RECRUITING
- Phase
- N/A
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Status
- RECRUITING
- Phase
- PHASE3
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
- Status
- COMPLETED
- Phase
- N/A
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
- Status
- RECRUITING
- Phase
- N/A
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
- Status
- RECRUITING
- Phase
- NA
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Elranatamab in R/R Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Lapelga vs Gastrofil
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
- Status
- RECRUITING
- Phase
- N/A